• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Echo Therapeutics, Ferndale Pharma launch drug-device trial

Echo Therapeutics, Ferndale Pharma launch drug-device trial

April 27, 2010 By MassDevice staff

ECTE logo

Echo Therapeutics Inc. (OTC:ECTE) and Ferndale Pharma Group Inc. enrolled the first patients in a clinical trial of Echo’s Prelude SkinPrep device and Ferndale’s 4 percent topical lidocaine, ahead of an application for 510(k) clearance for the drug-device combo from the Food & Drug Administration.

Franklin, Mass.-based Echo’s Prelude device is a needle-free, transdermal drug delivery system that ablates a thin layer of skin before a drug is applied.

In January the company said it was nearly ready to launch the clinical trial, having completed its development work on the product. The trial is designed to "evaluate the ability of the Prelude SkinPrep System to ablate the skin prior to application of OTC 4 percent lidocaine cream for local dermal anesthesia," according to a press release. Once it’s complete the companies plan to submit the 510(k) application to the FDA, likely later this year.

Echo said it licensed the rights to develop and commercialize the Prelude in the U.S. and the U.K. to Ferndale in May 2009, for an up-front payment of $750,000. Once the device wins FDA clearance another $750,000 milestone payment is due, plus $12.5 million "in milestone payments and guaranteed minimum royalty payments" and ongoing royalties on net sales, according to the release.

Echo chairman and president Dr. Patrick Mooney estimated in prepared remarks that the topical anesthetic market is worth more than $200 million a year and that the Prelude device "has the potential to grow it significantly."

Echo is also nearing readiness for a clinical trial of its Symphony tCGM transdermal glucose monitor, after a design breakthrough reduced the size of the device’s electrical component by a third.

Echo pulled in about $3.5 million in new investments late last year, $3 million from a private stock sale in November and another $562,000 from a group of backers in Philadelphia in December.

Filed Under: Business/Financial News, Drug-Device Combinations, News Well, Pharmaceutical Tagged With: Echo Therapeutics Inc., Ferndale Pharma Group Inc.

More recent news

  • NICE recommends Boston Scientific Farapulse pulsed field ablation tech
  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy